Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to -$2.9 million.

  • Palisade Bio's Income towards Parent Company rose 1867.19% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 2168.81%. This contributed to the annual value of -$14.9 million for FY2024, which is 1364.92% down from last year.
  • According to the latest figures from Q3 2025, Palisade Bio's Income towards Parent Company is -$2.9 million, which was up 1867.19% from -$2.8 million recorded in Q2 2025.
  • Over the past 5 years, Palisade Bio's Income towards Parent Company peaked at -$2.3 million during Q1 2025, and registered a low of -$33.5 million during Q2 2021.
  • For the 5-year period, Palisade Bio's Income towards Parent Company averaged around -$5.1 million, with its median value being -$3.6 million (2023).
  • As far as peak fluctuations go, Palisade Bio's Income towards Parent Company plummeted by 171888.15% in 2021, and later surged by 8932.65% in 2022.
  • Palisade Bio's Income towards Parent Company (Quarter) stood at -$3.0 million in 2021, then fell by 26.59% to -$3.9 million in 2022, then grew by 18.0% to -$3.2 million in 2023, then dropped by 7.19% to -$3.4 million in 2024, then rose by 13.53% to -$2.9 million in 2025.
  • Its Income towards Parent Company was -$2.9 million in Q3 2025, compared to -$2.8 million in Q2 2025 and -$2.3 million in Q1 2025.